CTMX — CytomX Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $955.50m
- $818.45m
- $76.20m
Annual income statement for CytomX Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K/A | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 37.3 | 53.2 | 101 | 138 | 76.2 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 153 | 154 | 108 | 113 | 98.6 |
| Operating Profit | -116 | -101 | -6.48 | 25 | -22.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -116 | -99.3 | 3.32 | 32.1 | -17.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -116 | -99.3 | -0.569 | 31.9 | -17.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -116 | -99.3 | -0.569 | 31.9 | -17.4 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -116 | -99.3 | -0.569 | 31.9 | -20.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.81 | -1.39 | -0.008 | 0.376 | -0.148 |